A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes

Boehringer Ingelheim

Status

Completed

Conditions

Diabetes Mellitus, Type 2

Treatments

Drug: Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor

Drug: Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor

Study type

Observational

Funder types

Industry

Identifiers

1245-0195

Details and patient eligibility

About

Non-interventional, multi-country cohort study using existing data and including adults (≥18 years) with a diagnosis of Type 2 diabetes mellitus.

Enrollment

327,624 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Dispensation or any other record of empagliflozin, any SGLT-2 inhibitor, or any DPP-4 inhibitor use during the study period
No dispensation or any other record of any other SGLT-2 inhibitor or DPP-4 inhibitor use during the preceding 12 months including at index date
Having a diagnosis of T2DM before the index date, based on ICD-10 codes or other available data

Exclusion criteria

Aged <18 years on the first dispensation date or date of the first record of empagliflozin, any SGLT-2 inhibitor or any DPP-4 inhibitor use
Type 1 diabetes mellitus
Secondary diabetes
Gestational diabetes
Having a diagnosis of ESRD during the 12 months before the index date
<12 months of available data before the index date, and/or no complete history of drug dispensations/other records of the drug use during this period
Missing or ambiguous data on age or sex